Marshall Wace
NVAX icon

Marshall Wace’s Novavax NVAX Stock Holding History

Marshall Wace’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.15M Sell
652,773
-513,424
-44% -$4.6M ﹤0.01% 1266
2026
Q1 		$9.49M Buy
1,166,197
+236,586
+25% +$2.14M 0.01% 1002
2025
Q4 		$6.25M Buy
929,611
+879,016
+1,737% +$6.63M 0.01% 1060
2025
Q3 		$439K Buy
+50,595
New +$394K ﹤0.01% 2279
2024
Q4 		– Sell
-148,917
Closed -$1.88M – 2876
2024
Q3 		$1.88M Sell
148,917
-213,773
-59% -$2.76M ﹤0.01% 1393
2024
Q2 		$4.59M Buy
+362,690
New +$3.65M 0.01% 1030
2022
Q3 		– Sell
-160,157
Closed -$8.23M – 3659
2022
Q2 		$8.23M Buy
160,157
+143,603
+867% +$7.44M 0.02% 1006
2022
Q1 		$1.22M Sell
16,554
-29,037
-64% -$2.59M ﹤0.01% 2359
2021
Q4 		$6.52M Buy
45,591
+29,731
+187% +$5.11M 0.01% 1170
2021
Q3 		$3.29M Sell
15,860
-25,045
-61% -$5.52M 0.01% 1206
2021
Q2 		$8.68M Sell
40,905
-9,853
-19% -$1.81M 0.04% 548
2021
Q1 		$9.2M Buy
50,758
+47,881
+1,664% +$9.54M 0.04% 497
2020
Q4 		$321K Buy
+2,877
New +$306K ﹤0.01% 1631

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Marshall Wace's NVAX Position: Q2 2026 in Review

Marshall Wace reduced its Novavax (NVAX) stake by 44% in Q2 2026, selling an estimated $4.6M and leaving 652,773 shares worth $6.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Marshall Wace first reported a position in NVAX in Q4 2020 and has held it in 13 quarters since. The position peaked at $9.49M in Q1 2026. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Marshall Wace held 652,773 shares of Novavax worth $6.15M as of Q2 2026.
  • Marshall Wace sold 513,424 Novavax shares in Q2 2026, an estimated $4.6M.
  • Novavax made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1266 holding.
  • Marshall Wace first reported a position in Novavax in Q4 2020 and has held it in 13 quarters since.
  • Marshall Wace's Novavax position peaked at $9.49M in Q1 2026.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.